Paid Clinical Trials Jersey City
Discover 1,460 paid clinical trials in Jersey City, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Tirzepatide & IxekizumabA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06857942
Conditions
Psoriasis
Overweight or Obesity
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tirzepatide
AmlitelimabA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sponsor:
Sanofi
Location:
Code:
NCT06181435
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Amlitelimab
Placebo
RemternetugA Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06653153
Conditions
Alzheimer's Disease
Eligibility Criteria
Sex: All
Age: 55 - 70+
Healthy Volunteers: Not accepted
Interventions
Remternetug
Placebo
LebrikizumabA Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06921759
Conditions
Atopic Hand and Foot Dermatitis
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Lebrikizumab
Placebo
AmlitelimabA Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sponsor:
Sanofi
Location:
Code:
NCT06407934
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Amlitelimab
Placebo
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Tobacco TrainingPediatric Residency Training On Tobacco
Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Location:
Code:
NCT00098215
Conditions
Tobacco Use Disorder
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Accepted
Interventions
Pediatric residency training on tobacco
StatinsStatins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Sponsor:
Rutgers, The State University of New Jersey
Location:
Code:
NCT05559164
Conditions
Cardiac Toxicity
Early-stage Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Lipitor 40mg Tablet
Liposomal Doxorubicin & CarboplatinOCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
Sponsor:
Mridula George, MD
Location:
Code:
NCT05949021
Conditions
Triple Negative Breast Cancer (TNBC)
Eligibility Criteria
Sex: Female
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Combination of liposomal doxorubicin
ANG-3070Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Sponsor:
Angion Biomedica Corp
Location:
Code:
NCT04939116
Conditions
Glomerular Disease
Proteinuria
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ANG-3070
Placebo
Genomic AnalysisTargeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
Sponsor:
Rutgers, The State University of New Jersey
Location:
Code:
NCT02688517
Conditions
Malignant Neoplasm
Eligibility Criteria
Sex: All
Age: 1+
Healthy Volunteers: Not accepted
Interventions
Cytology Specimen Collection Procedure
Laboratory Biomarker Analysis